drugset / Trial / NCT04229537
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of SCT-I10A combined SCT200 or SCT-I10A combined SCT200 plus chemotherapy in advanced esophageal squamous cell carcinoma and colorectal cancer
Timeline
- Start
- 2020-03-01
- Primary completion
- 2022-08-01
- Completion
- 2022-12-01
Publications
- Bai M, Lu Y, Shen L, Yin X, Gao S, Xia B, Fu Z, Zhang Z, Xie L, Ba Y. Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial. Cancer. 2025 Aug 15;131(16):e70046. doi: 10.1002/cncr.70046.
- Bai M, Lu Y, Shi C, Yang J, Li W, Yin X, Huang C, Shen L, Xie L, Ba Y. Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer. Cancer Biol Med. 2023 Dec 23;21(7):636-50. doi: 10.20892/j.issn.2095-3941.2023.0301.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finotonlimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 8 mg/kg | Intravenous |